How does Creative Biolabs' approach specifically overcome the systemic toxicity concerns associated with native IL-7?

Our core mandate is localization and latency. By using immunocytokine or prodrug platforms, we ensure the cytokine is either physically concentrated at the tumor site or chemically inactive in the systemic circulation. This precisely controls where the IL-7 can signal, leading to a significant reduction in non-target lymphoid organ proliferation.

How does the IL-7 strategy compare to using IL-2 in T-cell research?

IL-7 holds a major advantage as it preferentially supports the survival and expansion of cytotoxic T-cells and memory cells, while avoiding the Treg activation and vascular leak syndrome commonly associated with high-dose IL-2. Our engineered IL-7 constructs enhance this benefit by removing systemic exposure risks, maximizing the positive T-cell response.

Targeted IL-7 Delivery Engineering Services

Creative Biolabs provides leading-edge solutions to overcome the primary technical hurdles associated with potent cytokine research: non-specific activity and short half-life. We offer a comprehensive suite of customized engineering platforms, including Immunocytokines, Prodrug activation, Fc-Fusion PK optimization, and specialized viral vector development. Clients receive a fully characterized, de-risked IL-7 research construct, complete with detailed SAR, PK/PD, and functional potency data, enabling a smooth, accelerated transition into advanced pre-clinical development.

Introduction What We Can Offer How We Can Help Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us

Localized IL-7 Delivery for Systemic Tumor Immunity

Interleukin-7 (IL-7) is a critical cytokine for T-cell development and maintenance, offering enormous potential for T-cell research by robustly expanding cytotoxic T-lymphocytes (CTLs). However, achieving desired efficacy requires overcoming systemic toxicity from broad tissue distribution and its short in vivo half-life. The solution lies in precision engineering for localized expression. Published data and recent studies confirm that localized IL-7 expression, particularly via oncolytic viruses co-expressing IL-12, successfully shifts the efficacy window, generating systemic anti-tumor immunity and durable T-cell memory while greatly reducing off-target effects.

What We Can Offer

Proprietary Half-Life Extension

Utilization of Creative Biolabs' proprietary FcRn engagement technology and IL-7/receptor complex strategies to achieve superior in vivo half-life and optimized PK profiles that drastically reduce the necessary dosing frequency.

De-Risked Safety & Efficacy

Our designs incorporate rigorous preclinical evaluation focused on TME specificity and minimizing off-target lymphoid organ proliferation, allowing you to de-risk the crucial toxicity sections of your regulatory readiness package early.

Quality-by-Design (QbD) Cytokine Production

Application of stringent QbD principles from gene construction through final protein/vector purification guarantees the highest quality, stability, and batch-to-batch consistency for future large-scale manufacturing.

End-to-End Design and Execution

A true one-stop service covering rational design, in silico modeling, gene synthesis, high-yield expression, and full functional characterization, ensuring a seamless, efficient transition from concept to pre-clinical construct.

Targeted IL-7 Delivery Engineering Services at Creative Biolabs

Antibody mediated IL-7 Targeting Service

IL-7 is genetically fused to a monoclonal antibody (mAb) configured to recognize a tumor-specific antigen (TSA) or a TME-expressed target. This design operates as a guided therapeutic payload, achieving the concentration of high-potency IL-7 directly at the research site to maximize local therapeutic effect while minimizing systemic toxicity.

Why Choose Us?

Core Advantages	Unique Features
Powerful Combination Strategies	Our platforms are uniquely designed to co-express IL-7 with other potent immunomodulators like IL-12. This strategy is proven to induce systemic anti-tumor immunity (the abscopal effect) and dramatically sensitize distant, non-responding tumors to checkpoint blockade (ICB), a critical advantage for combination research.
De-Risked Safety Profile	Our focus on Prodrug and Immunocytokine design ensures the cytokine is largely inactive in systemic circulation, providing a crucial reduction in the risk of off-target lymphoproliferation and related off-target effects compared to native IL-7.
Durable Responses	Utilizing sustained local expression via viral vectors or engineered CAR-T cells (C7R), we overcome the challenge of a short half-life, ensuring long-term T-cell persistence and durable research presence.

Core Advantages

Unique Features

Powerful Combination Strategies

Our platforms are uniquely designed to co-express IL-7 with other potent immunomodulators like IL-12. This strategy is proven to induce systemic anti-tumor immunity (the abscopal effect) and dramatically sensitize distant, non-responding tumors to checkpoint blockade (ICB), a critical advantage for combination research.

De-Risked Safety Profile

Our focus on Prodrug and Immunocytokine design ensures the cytokine is largely inactive in systemic circulation, providing a crucial reduction in the risk of off-target lymphoproliferation and related off-target effects compared to native IL-7.

Durable Responses

Utilizing sustained local expression via viral vectors or engineered CAR-T cells (C7R), we overcome the challenge of a short half-life, ensuring long-term T-cell persistence and durable research presence.

Customer Reviews

FAQs

Related Services

Target-Specific IL-2 Delivery & Activation Engineering Services

Focused engineering of low-affinity IL-2 muteins (non-α variants) and targeted IC fusions. This service aims to preferentially activate CD8+ T-cells and NK cells via the IL-2Rβγ receptor, circumventing the activation of immunosuppressive Treg cells and minimizing systemic toxicity.

Learn More →

Tumor-Targeted IL-15 Delivery Engineering Services

Focuses on the next generation of IL-15 research constructs, utilizing IL-15Rα-Fc fusions (super-agonists) and targeted IC platforms to maximize NK and CTL expansion while optimizing PK and avoiding non-specific toxicity.